Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 4/20 | 0.35 |
| ▸ | GCGR | P47871 | 5/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119282 | 0.92 | BDKRB1 (0.42) | BDKRB1PDE3BPDE3A | |
| SCHEMBL5114297 | 0.88 | SLC2A1 (0.34) | GCGREPHX2 | |
| SCHEMBL5114280 | 0.86 | BDKRB1 (0.45) | BDKRB1GCGRTRPM8 | |
| SCHEMBL5118256 | 0.86 | SMN1; SMN2 (0.35) | BDKRB1PDE3BPDE3AEPHX2 | |
| SCHEMBL4192372 | 0.84 | BDKRB1 (0.52) | BDKRB1 | |
| SCHEMBL5114092 | 0.84 | BDKRB1 (0.43) | BDKRB1PDE3BPDE3A | |
| SCHEMBL5124690 | 0.83 | LMNA (0.41) | BDKRB1 | |
| SCHEMBL5119727 | 0.82 | BDKRB1 (0.38) | BDKRB1 | |
| SCHEMBL5117876 | 0.82 | BDKRB1 (0.38) | BDKRB1 | |
| SCHEMBL5125528 | 0.81 | BDKRB1 (0.52) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | BDKRB1 1217/4885GCGR 1878/4885SCN9A 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.